Phase I study of BAY 43-9006 (sorafenib), a Raf kinase and VEGFR inhibitor, combined with irinotecan (CPT-11) in advanced solid tumors

3115 Background: BAY 43–9006 (BAY), a Raf kinase and VEGFR inhibitor, inhibits tumor cell proliferation and angiogenesis. In preclinical studies BAY and irinotecan (CPT-11) had improved anti-tumor ...